Epilepsy and Menopause: Potential Implications for Pharmacotherapy

Drugs and Aging

Volumn 31, Issue 9, 2014, Pages 671-675

  Sveinsson, Olafur ^a   Tomson, Torbjörn ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT;

AGED; ELDERLY CARE; EPILEPSY; FEMALE; HUMAN; MENOPAUSE; PATHOPHYSIOLOGY; VERY ELDERLY; WOMEN'S HEALTH;

AGED; AGED, 80 AND OVER; ANTICONVULSANTS; EPILEPSY; FEMALE; HEALTH SERVICES FOR THE AGED; HUMANS; MENOPAUSE; WOMEN'S HEALTH;

EID: 84929512839     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-014-0201-5     Document Type: Article

References (37)

1. World Health Organisation. Epilepsy. http://www.who.int/topics/epilepsy. Accessed 13 Dec 2013.
2. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia. 1993;34(3):453–68.
3. Taubøll E, Luef G. Gender issues in epilepsy—the science of why it is special. Seizure. 2008;17:99–100.
4. Harden CL, Pennell PB. Neuroendocrine considerations in the treatment of men and women with epilepsy. Lancet Neurol. 2013;12(1):72–83.
5. Friedman MN, Geula C, Holmes GL, Herzog AG. GnRH-immunoreactive fiber changes with unilateral amygdala-kindled seizures. Epilepsy Res. 2002;52:73–7.
6. Quigg M, Kiely JM, Johnson ML, et al. Interictal and postictal circadian and ultradian luteinizing hormone secretion in men with temporal lobe epilepsy. Epilepsia. 2006;47:1452–9.
7. Luef G. Female issues in epilepsy: a critical review. Epilepsy Behav. 2009;15:78–82.
8. Cramer JA, Gordon J, Schachter S, et al. Women with epilepsy: hormonal issues from menarche through menopause. Epilepsy Behav. 2007;11:160–78.
9. Frye CA. Hormonal influences on seizures: basic neurobiology. Int Rev Neurobiol. 2008;83:27–77.
10. Logothetis J, Harner R, Morrell F, et al. The role of estrogens in catamenial exacerbation of epilepsy. Neurology. 1959;9:352–60.
11. Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia. 1997;38:1082–8.
12. Terasawa E, Timiras PS. Electrical activity during the estrous cycle of the rat: cyclic changes in limbic structures. Endocrinology. 1968;83:207–16.
13. Mattson RH, Cramer JA, Caldwell BV, et al. Treatment of seizures with medroxyprogesterone acetate: preliminary report. Neurology. 1984;34:1255–8.
14. Herzog AG. Progesterone therapy in women with epilepsy: a 3-year follow-up. Neurology. 1997;52:1917–8.
15. Scharfman HE, MacLusky NJ. The influence of gonadal hormones on neuronal excitability, seizures, and epilepsy in the female. Epilepsia. 2006;47:1423–30.
16. Herzog AG, Fowler KM, Smithson SD, et al. Progesterone vs placebo therapy for women with epilepsy: a randomized clinical trial. Neurology. 2012;78:1959–66.
17. North American Menopause Society. Menopause Core Curriculum Study Guide. 2nd ed. Cleveland: North American Menopause Society; 2002.
18. Soules MR, Sherman S, Parrott E, et al. Executive summary: stages of reproductive aging workshop (STRAW). Fertil Steril. 2001;76:874–8.
19. Harden CL, Koppel BS, Herzog AG, et al. Seizure frequency is associated with age at menopause in women with epilepsy. Neurology. 2003;61:451–5.
20. McAuley JW, Koshy SJ, Moore JL, et al. Characterization and health risk assessment of postmenopausal women with epilepsy. Epilepsy Behav. 2000;1:353–5.
21. Klein P, Serje A, Pezzulo JC. Premature ovarian failure in women with epilepsy. Epilepsia. 2001;42:1584–9.
22. Burger HG, Dudley EC, Robertson DM, et al. Hormonal changes in the menopause transition. Recent Prog Horm Res. 2002;57:257–75.
23. Harden CL, Pulver MC, Ravdin L, et al. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia. 1999;40:1402–7.
24. Abbasi F, Krumholz A, Kittner SJ, et al. Effects of menopause on seizures in women with epilepsy. Epilepsia. 1999;40:205–10.
25. McAuley JW, Sapna SJ, Moore JL, et al. Characterization and health risk assessment of postmenopausal women with epilepsy. Epilepsy Behav. 2000;1(353–355):23.
26. Tomson T, Lukic S, Ohman I. Are lamotrigine kinetics altered in menopause? Observations from a drug monitoring database. Epilepsy Behav. 2010;19:86–8.
27. Wegner I, Edelbroek PM, Bulk S, et al. Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives. Neurology. 2009;73:1388–93.
28. Wegner I, Wilhelm AJ, Sander JW, et al. The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study. Epilepsy Behav. 2013;29:217–21.
29. Harden CL, Herzog AG, Nikolov BG, et al. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. Epilepsia. 2006;47:1447–51.
30. Mattson RH, Gidal BE. Fractures, epilepsy, and antiepileptic drugs. Epilepsy Behav. 2004;5(Suppl. 2):S36–40.
31. Pack A. Bone health in people with epilepsy: is it impaired and what are the risk factors? Seizure. 2008;17(2):181–6.
32. Zare M, Ghazvini MR, Dashti M, et al. Bone turnover markers in epileptic patients under chronic valproate therapy. J Res Med Sci. 2013;18:338–40.
33. Jetté N, Lix LM, Metge CJ, et al. Association of antiepileptic drugs with nontraumatic fractures: a population-based analysis. Arch Neurol. 2011;68:107–12.
34. Pack AM, Morrell MJ, Randall A, et al. Bone health in young women with epilepsy after 1 year of antiepileptic drug monotherapy. Neurology. 2008;70(18):1586–93.
35. Mikati MA, Dib L, Yamout B, et al. Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. Neurology. 2006;67(11):2005–14.
36. Cardozo L, Bachmann G, McClish D, et al. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1998;92:722–7.
37. Erel T, Guralp O. Epilepsy and menopause. Arch Gynecol Obstet. 2011;283(4):755–9.